(RTTNews) - Cytokinetics (CYTK) presented data from the Phase 1 study of CK-4021586, or CK-586. The study met its primary and secondary objectives to assess the safety, tolerability and pharmacokinetics of single and multiple oral doses of CK-586. The company said the data support the advancement of CK-586 to a Phase 2 trial in patients with heart failure with preserved ejection fraction which is expected to begin in fourth quarter, 2024.
"The results from this Phase 1 study replicate pre-clinical findings that show CK-586 directly reduces cardiac contractility at the level of the sarcomere. Importantly, CK-586 was observed to have a shallow and predictable PK/PD relationship and half-life that enables a once-daily fixed dosing regimen in patients with HFpEF," said Stuart Kupfer, Senior Vice President, Chief Medical Officer.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
